PLX-200 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病1

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04637282
(ClinicalTrials.gov)
December 1, 20224/11/2020Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) DiseaseJuvenile Neuronal Ceroid LipofuscinosisDrug: PLX-200;Drug: PlaceboPolaryx Therapeutics, Inc.NULLNot yet recruiting6 Years18 YearsAll39Phase 3NULL